Why the study?
Should clinicians treat osteopenic women 65 years of age or older who are at a high risk for fracture with medications to prevent fractures?
Should clinicians treat osteopenic women 65 years of age or older who are at a high risk for fracture with medications to prevent fractures?
The American College of Physicians issued an updated clinical practice guideline recommending shared decision-making for the pharmacological treatment of osteopenic women aged 65 and older at high risk for fracture.
Supports individualized decisions on pharmacotherapy for high-risk osteopenic women ≥65; leaves open optimal thresholds pending higher-quality evidence.
ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
No takes yet. Share an insight, caveat, or question.
Qaseem et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: